Biogen Forecast, price target & analysts
Biogen Target price 2025 - Analyst rating & recommendation
Biogen Classifications & Recommendation:
Biogen Price Target
| Target Price | $181.11 |
| Price | $119.12 |
| Potential | 52.04% |
| Number of Estimates | 27 |
| 27 Analysts have issued a price target Biogen 2026 . The average Biogen target price is $181.11. This is 52.04% higher than the current stock price. The highest price target is $300.00 151.85% , the lowest is $115.00 3.46% . | |
| A rating was issued by 37 analysts: 16 Analysts recommend Biogen to buy, 21 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2026 of 52.04% . Most analysts recommend the Biogen stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2029
31 Analysts have issued a sales forecast Biogen 2025 . The average Biogen sales estimate is $9.2b . This is 0.94% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $9.5b 3.03% , the lowest is $8.9b 3.85% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $9.3b | 1.60% |
|---|---|---|
| 2025 | $9.2b | 0.94% |
| 2026 | $9.1b | 1.28% |
| 2027 | $9.2b | 1.08% |
| 2028 | $9.3b | 1.88% |
| 2029 | $9.3b | 0.16% |
11 Analysts have issued an Biogen EBITDA forecast 2025. The average Biogen EBITDA estimate is $3.3b . This is 18.35% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.9b 40.17% , the lowest is $2.7b 2.12% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $2.8b | 31.57% |
|---|---|---|
| 2025 | $3.3b | 18.35% |
| 2026 | $3.3b | 0.42% |
| 2027 | $3.4b | 1.65% |
| 2028 | $4.1b | 22.42% |
| 2029 | $4.9b | 20.57% |
EBITDA Margin
| 2024 | 30.19% | 33.71% |
|---|---|---|
| 2025 | 36.07% | 19.48% |
| 2026 | 36.38% | 0.86% |
| 2027 | 36.58% | 0.55% |
| 2028 | 43.96% | 20.17% |
| 2029 | 52.92% | 20.38% |
12 Biogen Analysts have issued a net profit forecast 2025. The average Biogen net profit estimate is $1.8b . This is 11.88% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.2b 34.88% , the lowest is $1.4b 14.91% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $1.6b | 40.40% |
|---|---|---|
| 2025 | $1.8b | 11.78% |
| 2026 | $2.1b | 16.91% |
| 2027 | $2.2b | 4.15% |
| 2028 | $2.6b | 17.09% |
| 2029 | $2.7b | 2.01% |
Net Margin
| 2024 | 17.61% | 42.68% |
|---|---|---|
| 2025 | 19.87% | 12.86% |
| 2026 | 23.53% | 18.42% |
| 2027 | 24.24% | 3.02% |
| 2028 | 27.86% | 14.93% |
| 2029 | 28.37% | 1.83% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
12 Analysts have issued a Biogen forecast for earnings per share. The average Biogen EPS is $12.51 . This is 11.90% higher than earnings per share in the financial year 2024. The highest EPS forecast is $15.08 34.88% , the lowest is $9.51 14.94% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $11.19 | 40.40% |
|---|---|---|
| 2025 | $12.51 | 11.80% |
| 2026 | $14.62 | 16.87% |
| 2027 | $15.23 | 4.17% |
| 2028 | $17.83 | 17.07% |
| 2029 | $18.19 | 2.02% |
P/E ratio
| Current | 10.65 | 59.18% |
|---|---|---|
| 2025 | 9.52 | 10.61% |
| 2026 | 8.15 | 14.39% |
| 2027 | 7.82 | 4.05% |
| 2028 | 6.68 | 14.58% |
| 2029 | 6.55 | 1.95% |
Based on analysts' sales estimates for 2025, the Biogen stock is valued at an EV/Sales of 2.37 and an P/S ratio of 1.90 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 2.35 | 39.90% |
|---|---|---|
| 2025 | 2.37 | 0.95% |
| 2026 | 2.40 | 1.29% |
| 2027 | 2.38 | 1.07% |
| 2028 | 2.33 | 1.84% |
| 2029 | 2.33 | 0.16% |
P/S ratio
| Current | 1.88 | 42.55% |
|---|---|---|
| 2025 | 1.90 | 0.95% |
| 2026 | 1.92 | 1.30% |
| 2027 | 1.90 | 1.07% |
| 2028 | 1.87 | 1.84% |
| 2029 | 1.87 | 0.16% |
Current Biogen Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Hold
➜
Hold
|
Unchanged | Apr 25 2025 |
| Goldman Sachs |
Buy
➜
Buy
|
Unchanged | Apr 23 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Apr 22 2025 |
| Needham |
Hold
➜
Hold
|
Unchanged | Apr 16 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Apr 09 2025 |
| Argus Research |
Buy
➜
Hold
|
Downgrade | Apr 04 2025 |
| Piper Sandler |
Neutral
➜
Neutral
|
Unchanged | Feb 18 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Needham:
Hold
➜
Hold
|
Apr 25 2025 |
|
Unchanged
Goldman Sachs:
Buy
➜
Buy
|
Apr 23 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Apr 22 2025 |
|
Unchanged
Needham:
Hold
➜
Hold
|
Apr 16 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Apr 09 2025 |
|
Downgrade
Argus Research:
Buy
➜
Hold
|
Apr 04 2025 |
|
Unchanged
Piper Sandler:
Neutral
➜
Neutral
|
Feb 18 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
